Zai Lab Limited - ZLAB
About Gravity Analytica
Recent News
- 12.15.2025 - argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
- 12.15.2025 - Zai Lab Announces Participation in Investor Conference in January 2025
- 12.15.2025 - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
- 12.15.2025 - Zai Lab Announces Updates to China’s National Reimbursement Drug List
- 12.15.2025 - Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
- 12.15.2025 - Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
- 12.15.2025 - Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
- 12.15.2025 - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
- 12.15.2025 - Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
- 12.15.2025 - Zai Lab Announces Pricing of Public Offering of American Depositary Shares